• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲姑息治疗研究协作组与亚洲恶病质工作组制定的肺癌预后与诊断标准之间关联的比较研究

Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia.

作者信息

Katsushima Utae, Fukushima Takuya, Nakano Jiro, Ogushi Naoya, Fujii Kazuki, Nagata Yutaro, Kamisako Keisuke, Okuno Yukiko, Okazaki Yuta, Nakanishi Kentaro, Yoshida Kiyori, Ikoma Tatsuki, Takeyasu Yuki, Yamanaka Yuta, Yoshioka Hiroshige, Hase Kimitaka, Kurata Takayasu

机构信息

Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan.

Faculty of Rehabilitation, Kansai Medical University, Osaka, Japan.

出版信息

Thorac Cancer. 2025 Jan;16(2):e15503. doi: 10.1111/1759-7714.15503. Epub 2024 Dec 9.

DOI:10.1111/1759-7714.15503
PMID:39654007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11735465/
Abstract

BACKGROUND

Cachexia is a poor prognostic factor in many advanced cancers. Cachexia diagnostic criteria of the European Palliative Care Research Collaboration (EPCRC) may underestimate cachexia in Asians; therefore, new criteria have been proposed by the Asian Working Group for Cachexia (AWGC). We compared both criteria to determine differences in diagnostic rates and their association with lung cancer prognosis.

PATIENTS AND METHODS

This single-center, retrospective cohort study considered lung cancer outpatients receiving chemotherapy. Survival was analyzed using Kaplan-Meier curves and log-rank tests. The association between cachexia diagnosis and prognosis was examined for each set of criteria using a Cox proportional hazards model. C-statistic analysis was performed to compare the discriminative power for prognosis.

RESULTS

Among the 106 participants analyzed (median age, 75 [71-79] years; 75 males [70.8%]; 91 [85.9%] with performance status [PS] 0-1), 58 (54.7%) and 77 (72.6%) cachexia cases were diagnosed using the EPCRC and AWGC criteria, respectively. The latter encompassed all but one patient diagnosed using the EPCRC criteria. Patients with cachexia had a significantly poorer prognosis according to both criteria (EPCRC, p = 0.002; AWGC, p = 0.001). Both criteria had almost equal discriminative power for prognosis (EPCRC, C-statistic = 0.658; AWGC, C-statistic = 0.658). CRP in the AWGC criteria was most strongly related to prognosis.

CONCLUSIONS

Cachexia was an independent poor prognostic factor in lung cancer patients receiving chemotherapy under the AWGC and EPCRC criteria, both of which had similar prognostic discriminatory power. Among CRP, anorexia, and grip strength, elevated CRP may be the most prognostically relevant parameter in the AWGC criteria.

摘要

背景

恶病质是许多晚期癌症患者预后不良的因素。欧洲姑息治疗研究协作组(EPCRC)的恶病质诊断标准可能会低估亚洲人的恶病质情况;因此,亚洲恶病质工作组(AWGC)提出了新的标准。我们比较了这两种标准,以确定诊断率的差异及其与肺癌预后的关联。

患者与方法

这项单中心回顾性队列研究纳入了接受化疗的肺癌门诊患者。采用Kaplan-Meier曲线和对数秩检验分析生存率。使用Cox比例风险模型检查每组标准下恶病质诊断与预后之间的关联。进行C统计分析以比较预后判别能力。

结果

在分析的106名参与者中(中位年龄75[71-79]岁;75名男性[70.8%];91名[85.9%]的体能状态[PS]为0-1),分别使用EPCRC和AWGC标准诊断出58例(54.7%)和77例(72.6%)恶病质病例。后者涵盖了除1例使用EPCRC标准诊断的患者外的所有患者。根据这两种标准,恶病质患者的预后均明显较差(EPCRC,p = 0.002;AWGC,p = 0.001)。两种标准对预后的判别能力几乎相同(EPCRC,C统计量= 0.658;AWGC,C统计量= 0.658)。AWGC标准中的CRP与预后的相关性最强。

结论

根据AWGC和EPCRC标准,恶病质是接受化疗的肺癌患者独立的预后不良因素,二者具有相似的预后判别能力。在CRP、厌食和握力中,CRP升高可能是AWGC标准中最具预后相关性的参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/c1de701ae905/TCA-16-e15503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/c3a8b25b8d14/TCA-16-e15503-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/5d733b247b89/TCA-16-e15503-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/d3498f09595b/TCA-16-e15503-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/c1de701ae905/TCA-16-e15503-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/c3a8b25b8d14/TCA-16-e15503-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/5d733b247b89/TCA-16-e15503-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/d3498f09595b/TCA-16-e15503-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cca/11735465/c1de701ae905/TCA-16-e15503-g001.jpg

相似文献

1
Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia.欧洲姑息治疗研究协作组与亚洲恶病质工作组制定的肺癌预后与诊断标准之间关联的比较研究
Thorac Cancer. 2025 Jan;16(2):e15503. doi: 10.1111/1759-7714.15503. Epub 2024 Dec 9.
2
Validity of the diagnostic criteria from the Asian Working Group for Cachexia in advanced cancer.晚期癌症患者恶液质亚洲工作组诊断标准的有效性。
J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):370-379. doi: 10.1002/jcsm.13408. Epub 2023 Dec 19.
3
Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.可治愈胃癌患者中,亚洲癌症恶病质共识工作组定义的癌症恶病质的特征和预后影响。
Clin Nutr. 2024 Jun;43(6):1524-1531. doi: 10.1016/j.clnu.2024.05.018. Epub 2024 May 10.
4
Impacts of fluid retention on prognostic abilities of cachexia diagnostic criteria in cancer patients with refractory cachexia.液体潴留对难治性恶病质癌症患者恶病质诊断标准预后能力的影响。
Clin Nutr ESPEN. 2024 Apr;60:373-381. doi: 10.1016/j.clnesp.2024.02.026. Epub 2024 Feb 29.
5
Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure.亚洲老年心力衰竭患者中采用新定义诊断的恶病质的患病率及预后价值
J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2660-2668. doi: 10.1002/jcsm.13610. Epub 2024 Nov 5.
6
Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.胃癌患者 AWGC-cachexia 与 GLIM-malnutrition 的比较。
Eur J Surg Oncol. 2024 Oct;50(10):108580. doi: 10.1016/j.ejso.2024.108580. Epub 2024 Aug 2.
7
AWGC2023 cachexia consensus as a valuable tool for predicting prognosis and burden in Chinese patients with cancer.AWGC2023恶病质共识作为预测中国癌症患者预后和负担的重要工具。
J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):2084-2093. doi: 10.1002/jcsm.13555. Epub 2024 Aug 27.
8
Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia.亚洲恶病质的诊断与转归:亚洲恶病质工作组共识报告
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1949-1958. doi: 10.1002/jcsm.13323. Epub 2023 Sep 5.
9
Prevalence and prognostic significance of cachexia diagnosed by novel definition for Asian population among Chinese cirrhotic patients.新型定义诊断的恶病质在亚洲人群中国肝硬化患者中的患病率及预后意义
Arch Gerontol Geriatr. 2025 Jun;133:105833. doi: 10.1016/j.archger.2025.105833. Epub 2025 Mar 17.
10
Prevalence and relevance of cachexia as diagnosed by two different definitions in patients undergoing hemodialysis: A retrospective and exploratory study.两种不同定义诊断的血液透析患者恶病质的患病率及相关性:一项回顾性和探索性研究。
Arch Gerontol Geriatr. 2024 Sep;124:105447. doi: 10.1016/j.archger.2024.105447. Epub 2024 Apr 15.

引用本文的文献

1
Cancer cachexia onset and survival outcomes in metastatic colorectal cancer: Comparative assessment of the asian working group for cachexia and the European palliative care research collaborative criteria, and utility of modified glasgow prognostic score.转移性结直肠癌的癌症恶病质发病情况及生存结局:亚洲恶病质工作组与欧洲姑息治疗研究协作组标准的比较评估,以及改良格拉斯哥预后评分的效用
Int J Colorectal Dis. 2025 Jul 25;40(1):164. doi: 10.1007/s00384-025-04962-2.

本文引用的文献

1
Validity of the diagnostic criteria from the Asian Working Group for Cachexia in advanced cancer.晚期癌症患者恶液质亚洲工作组诊断标准的有效性。
J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):370-379. doi: 10.1002/jcsm.13408. Epub 2023 Dec 19.
2
Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia.亚洲恶病质的诊断与转归:亚洲恶病质工作组共识报告
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1949-1958. doi: 10.1002/jcsm.13323. Epub 2023 Sep 5.
3
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study.
《日本肺癌登记研究:恶病质的流行病学、危险因素及对患者预后的影响》。
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1274-1285. doi: 10.1002/jcsm.13216. Epub 2023 Mar 10.
4
The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer.晚期肺癌炎症指数是肺癌患者总生存期的最佳炎症生物标志物。
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2504-2514. doi: 10.1002/jcsm.13032. Epub 2022 Jul 14.
5
Pathological features of tissues and cell populations during cancer cachexia.癌症恶病质期间组织和细胞群体的病理特征。
Cell Regen. 2022 Apr 20;11(1):15. doi: 10.1186/s13619-022-00108-9.
6
Updates in Cancer-Related Symptom Management of Anorexia and Cachexia Syndrome.癌症相关厌食和恶病质综合征症状管理的最新进展。
Semin Oncol Nurs. 2022 Feb;38(1):151254. doi: 10.1016/j.soncn.2022.151254.
7
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.癌症恶病质对晚期非小细胞肺癌患者免疫检查点抑制剂的脱敏作用
JTO Clin Res Rep. 2020 Mar 4;1(2):100020. doi: 10.1016/j.jtocrr.2020.100020. eCollection 2020 Jun.
8
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines.成人癌症恶病质:ESMO 临床实践指南。
ESMO Open. 2021 Jun;6(3):100092. doi: 10.1016/j.esmoop.2021.100092.
9
Associations of low handgrip strength with cancer mortality: a multicentre observational study.握力低与癌症死亡率的关联:一项多中心观察性研究。
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1476-1486. doi: 10.1002/jcsm.12614. Epub 2020 Sep 10.
10
Management of Cancer Cachexia: ASCO Guideline.癌症恶病质的管理:ASCO 指南。
J Clin Oncol. 2020 Jul 20;38(21):2438-2453. doi: 10.1200/JCO.20.00611. Epub 2020 May 20.